TNFSF10 and neoplasm: The fusion of anti‐CLL1 with TRAIL is proposed to facilitate the anchoring of TRAIL to the neutrophil surface, thereby enhancing its cytotoxicity against tumor cells and simultaneously increasing the ADCC effect of antibody drugs [122].